Windtree Therapeutics Announces Issuance of New Dual Mechanism SERCA2a Activator Patent
Compounds that activate SERCA2a may lead to novel therapies for heart failure WARRINGTON, Pa. , April 17, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions for cardiovascular
Article Date
April 17, 2023
This article is featured on another website.
Go to article
March 26, 2026
pharmaphorum – BIO‑Europe Spring 2026: In conversation with Marjorie Sidhoum, Vice President of Business Development and Corporate Communications at Kainova Therapeutics
March 26, 2026
pharmaphorum – BIO‑Europe Spring 2026: In conversation with Marjorie Sidhoum, Vice President of Business Development and Corporate Communications at Kainova Therapeutics
April 20, 2026
Meet HiRO at COG New England Conference on April 28-29!
HiRO to Attend COG New England Conference, April 28–29 Clinical development is becoming increasingly global,…
April 20, 2026
Meet HiRO at COG New England Conference on April 28-29!
HiRO to Attend COG New England Conference, April 28–29 Clinical development is becoming increasingly global,…